Adma Biologics (ADMA) Gains But Lags Market: What You Should Know
In the latest trading session, Adma Biologics (ADMA) closed at $5.26, marking a +1.54% move from the previous day. The stock fell short of the S&P 500, which registered a gain of 2.11% for the day. At the same time, the Dow added 1.18%, and the tech-heavy Nasdaq gained 2.96%.
Shares of the infectious disease drug developer have appreciated by 2.57% over the course of the past month, underperforming the Medical sector's gain of 3.98% and the S&P 500's gain of 3.08%.
Investors will be eagerly watching for the performance of Adma Biologics in its upcoming earnings disclosure. The company's earnings report is set to be unveiled on February 28, 2024. The company's upcoming EPS is projected at $0.02, signifying a 133.33% increase compared to the same quarter of the previous year. Meanwhile, our latest consensus estimate is calling for revenue of $73.5 million, up 47.06% from the prior-year quarter.
Furthermore, it would be beneficial for investors to monitor any recent shifts in analyst projections for Adma Biologics. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Therefore, positive revisions in estimates convey analysts' confidence in the company's business performance and profit potential.
Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. As of now, Adma Biologics holds a Zacks Rank of #2 (Buy).
From a valuation perspective, Adma Biologics is currently exchanging hands at a Forward P/E ratio of 23.19. This indicates a premium in contrast to its industry's Forward P/E of 21.96.
The Medical - Biomedical and Genetics industry is part of the Medical sector. With its current Zacks Industry Rank of 89, this industry ranks in the top 36% of all industries, numbering over 250.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ADMA Biologics Inc (ADMA) : Free Stock Analysis Report
